Zobrazeno 101 - 110
of 165
pro vyhledávání: '"Deric L. Wheeler"'
Autor:
Deric L. Wheeler, Terry D. Oberley, Nancy E. Dreckschmidt, Eric G. Verwiebe, Aaron P. Jansen, Ajit K. Verma
Publikováno v:
International Journal of Cancer. 93:635-643
To define the in vivo role of individual PKC isoforms in mouse skin carcinogenesis, we previously characterized FVB/n transgenic mice that over-expressed epitope-tagged PKC delta (T7-PKC delta) or PKC epsilon (T7-PKC epsilon) isoforms under the regul
Autor:
Mosmi Surati, Ravi Salgia, Everett E. Vokes, Ajit Bharti, Maria Tretiakova, Deric L. Wheeler, Todd Hembrough, Immanuel Dhanasingh, Qudsia Arif, Toni M. Brand, Rajani Kanteti, Suvobroto Nandi, Cleo E. Rolle, Aliya N. Husain, Soheil Yala
Small cell lung cancer (SCLC) is a devastating disease, and current therapies have not greatly improved the 5-year survival rates. Topoisomerase (Top) inhibition is a treatment modality for SCLC; however, the response is short lived. Consequently, ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba835ab53e8fe472a99da196142d1a7d
https://europepmc.org/articles/PMC4286701/
https://europepmc.org/articles/PMC4286701/
Autor:
Chunrong, Li, Toni M, Brand, Mari, Iida, Shyhmin, Huang, Eric A, Armstrong, Albert, van der Kogel, Deric L, Wheeler
Publikováno v:
Discovery medicine. 16(87)
HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. In the present study, we investigated the capacity of the HER3 blocking antibody, U3-1287/AMG888, to modulate the in vitro and in vivo radiation resp
NSCLC is a deadly disease that is driven by a multitude of factors. One of these factors is the epidermal growth factor receptor (EGFR). One of the most prominent molecular targeting agents to the EGFR is the antibody cetuximab. However, most patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d7dc0a60fc89d9539f519059bab12ad
https://doi.org/10.21236/ada599892
https://doi.org/10.21236/ada599892
Autor:
Emily F. Dunn, Deric L. Wheeler
Publikováno v:
Cancer Biology & Therapy. 8:1648-1650
Commentary to: Induction of apoptosis by lupeol in human epidermoid carcinoma A431 cells through regulation of mitochondrial, Akt/PKB and NF-kappaB signaling pathways Sahdeo Prasad, Esha Madan, Nidhi Nigam, Preeti Roy, George Jasmine, Yogeshwer Shukl
Publikováno v:
Cancer Biology & Therapy. 7:1095-1097
Commentary to:Anti-ErbB4 targeted therapy combined with radiation therapy in prostate cancer: Results of in-vitro and in-vivo studiesAKIVA VEXLER, GHALIB LIDAWI, VERED LOEW, ITAY BARNEA, VICTORIYA KARAUSH, ALEXANDER SHTABSKY, RAMI BEN-YOSEF
Autor:
Mari Iida, Megan M. Starr, Deric L. Wheeler, Toni M. Brand, Matthew J. Wleklinski, Neha Luthar
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 8, p e71518 (2013)
PLoS ONE, Vol 8, Iss 8, p e71518 (2013)
Nuclear localized HER family receptor tyrosine kinases (RTKs) have been observed in primary tumor specimens and cancer cell lines for nearly two decades. Inside the nucleus, HER family members (EGFR, HER2, and HER3) have been shown to function as co-
Autor:
Marieke M G Verheijen, Johannes H.A.M. Kaanders, Albert J. van der Kogel, Hanneke Stegeman, Paul N. Span, Johan Bussink, Mari Iida, Wenny J.M. Peeters, Deric L. Wheeler, Reidar Grénman
Publikováno v:
Molecular Cancer
Background: Kinases downstream of growth factor receptors have been implicated in radioresistance and are, therefore, attractive targets to improve radiotherapy outcome in head and neck squamous cell carcinoma (HNSCC) patients. Methods: An antibody-b
Autor:
Kurt R. Oettel, Toni M. Brand, Chong Zhang, Mari Iida, Toby C. Campbell, David T. Yang, Anne M. Traynor, Tien Hoang, Hilary R. Hernan, Ravi Salgia, Deric L. Wheeler, Tracey L. Weigel, KyungMann Kim
Introduction Nuclear EGFR (nEGFR) has been identified in various human tumor tissues, including cancers of the breast, ovary, oropharynx, and esophagus, and has predicted poor patient outcomes. We sought to determine if protein expression of nEGFR is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30a76746bcc604fa1072af7cbf2fa259
https://europepmc.org/articles/PMC3679338/
https://europepmc.org/articles/PMC3679338/
Autor:
Albert J. van der Kogel, Hanneke Stegeman, Johan Bussink, Paul N. Span, Mari Iida, Deric L. Wheeler, Johannes H.A.M. Kaanders
Publikováno v:
Radiotherapy and Oncology, 106, 383-9
Radiotherapy and Oncology, 106, 3, pp. 383-9
Radiotherapy and Oncology, 106, 3, pp. 383-9
Item does not contain fulltext BACKGROUND AND PURPOSE: EGFR-inhibitor Cetuximab (C225) improves the efficacy of radiotherapy in only a subgroup of HNSCC patients. Identification of predictive tumor characteristics is essential to improve patient sele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43cbe40c9cbc2b166483ef32283af52
https://doi.org/10.1016/j.radonc.2013.02.001
https://doi.org/10.1016/j.radonc.2013.02.001